Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > CGON 35% 12 months CR?
View:
Post by enriquesuave on May 03, 2024 1:31pm

CGON 35% 12 months CR?

Looks like they just presented data and from what I understand 29 out of 83 patients have maintained.  They treated 105 patients and 75% have achieved a CR at anytime.  22 patients are still pending data at 12 months.  So 29 out of 83 so far = 34.9% CR at 12 months. Seems like we are beating them badly. IMHO time will tell .  Will we hit $4 USD Billion MC like them when we get BTD?
Comment by Eoganacht on May 03, 2024 2:36pm
Yes it looks like 34.9% CRR at 12 months. And this is down to 20% CRR at 21 months ! Here is a link to their presentation: Pivotal Results from BOND-003 The results and swimmers plot are on slide 8. 6   month DOR  = 52 out of 97 patients = 54% 12 month DOR  = 29 out of 83 patients= 34.9% 21 months DOR = 14 out of 69 patients = 20%
Comment by enriquesuave on May 03, 2024 3:34pm
Nice find!  We are killing them in our durable and longer term data data it seems so far!  IMHO  
Comment by Eoganacht on May 03, 2024 4:06pm
At AUA 2025 Theralase will probably give a similar presentation except that the number of treatments will be 2 or 3 rather than 18 - 24 and the 24 month CRR will be greater than 30% rather than 20% IMHO
Comment by enriquesuave on May 03, 2024 4:20pm
By then we will also have hit a $5 Billion USD MC like our competitors!  Hopefully   
Comment by Alamir1111 on May 03, 2024 4:42pm
 Min.10 bill is the asking price  
Comment by Alamir1111 on May 03, 2024 5:01pm
Market estimate for pain dementia viruses cancer etc is about 500 bill  or more 10% of that is??
Comment by Yajne on May 03, 2024 5:03pm
Thanks for posting Eogan! I also found slide 16 "collaborators" interesting, includes some familiar names...Peter Black (UBC), Neal Shore (Carolina), Ashish Kamat (MD Anderson). With multiple trials happening for these guys, I always wonder how much priority Ruvidar gets at its clinical study sites
Comment by Alamir1111 on May 03, 2024 6:16pm
Interesting would be to see the numbers each facility treated ??
Comment by StevenBirch on May 03, 2024 6:36pm
It seems as if you're almost waiting in line with so many ongoing trials, let's hope TLT is next in line! Maybe these perceived 'delays' have nothing to do with TLT, that may upset some people.
Comment by toade1313 on May 03, 2024 7:34pm
Even assuming the delays have nothing to do with TLT,  the reason(s) for the delay should be communicated by TLT management.
Comment by stocksnbonds458 on May 06, 2024 8:48am
Very true Toade, it's very close to 1 year now since the FDA asked for some clarification on TLT data submitted as part of the Pre-BTD application. In fact, it was last June, so next month is 1 year!! ALL Shareholders deserve a VERY detailed explanation.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250